Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A panel consisting of miRNA-122-5p + miRNA-486-5p + miRNA-142-3p distinguished HCC from cirrhosis (AUC = 0.94; sensitivity = 80%, specificity = 95%; <i>p</i> < 0.001), outperforming AFP (AUC = 0.64, <i>p</i> = 0.065).
|
30781550 |
2019 |
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ROC analysis revealed that hsa-miR-122-5p, hsa-miR-223 and hsa-miR-29c-3p identified patients with ≥F2 fibrosis with area under the curve (AUC) =0.745, 0.631 and 0.670, respectively. hsa-miR-122-5p identified patients with ≥F3 disease (AUC=0.783). hsa-miR-122-5p, hsa-miR-223 and hsa-miR-29c-3p identified patients with cirrhosis with AUC=0.776, 0.617 and 0.619, respectively.
|
30783469 |
2019 |
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggested that miR-34a, miR-122, and miR-885-5p levels may be more related to the inflammatory process and ongoing hepatocyte damage in patients with cirrhosis.
|
29935272 |
2018 |
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to the median relative expression of miR-122 after TACE/before TACE (miR-122 ratio) in liver cirrhosis patients (n=57), the patients with a higher miR-122 ratio had significantly longer disease-specific survival, compared with that of the patients with the lower miR-122 ratio (P=0.0461).
|
30127924 |
2018 |
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas under the curve (AUC) were 0.675 for miR-122, 0.791 for AFP and 0.846 for PIVKA-II, while their combination improved the discrimination power between cirrhosis and HCC (AUC=0.918).
|
28650134 |
2017 |
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time polymerase chain reaction was utilized to determine serum miR-122 expression in 102 patients with different liver diseases [CHBLF (n = 58), acute hepatitis B (n = 10), chronic hepatitis B (n = 22) and hepatitis B-related cirrhosis (n = 12)] and 23 healthy controls.
|
27059663 |
2016 |
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, alterations in intrahepatic miRNA networks have been associated with liver disease including hepatitis, steatosis, cirrhosis and hepatocellular carcinoma (HCC). miR-122 is the most frequent miRNA in the adult liver, and a central player in liver biology and disease.
|
25308172 |
2015 |
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-122 levels were almost normal in patients with cirrhosis without ongoing liver damage, but were elevated when liver injury was present.
|
25039534 |
2015 |
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-122 was further decreased in HCCs relative to non-tumor LC at the age of 18 weeks.
|
25117675 |
2014 |
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum levels of miR-122 and miR-29 in 20 patients with hepatocellular carcinoma (HCC), 20 patients with liver cirrhosis (LC), 29 patients with chronic hepatitis B (CHB), 20 cases of hepatitis B virus carriers (ASC), and 20 healthy controls (HC) were determined by a fluorescence real-time quantitative PCR method and then evaluated by clinical correlation analysis.
|
25299106 |
2014 |
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum miR-1 and miR-122 concentrations did not differ significantly between patients with HCC and liver cirrhosis.
|
23810247 |
2013 |